Yea, this stock can't jump from .10 to $5 on FDA fast track, let alone $12-18 on phase 4 approval. That would be unrealistic.
Unless you consider that the stock was trading at .002 and went to .18 in a matter of 2 months on settlement of a lawsuit and the placement of a new director.
I guess such a jump on entering a virtually untapped market of repairing and regenerating a human heart after chronic heart failure would be reasonable. Holy cow. I never thought of it that way.
They've had a few buyout offers already, right? Can you imagine the offers with FDA approval? They'll probably come in with more offers fairly quick and at a much higher price per share buyout!
News 
Market Data 
Discover 
